iRegene Therapeutics, a Wuhan-based biotechnology company specializing in the development of AI-enhanced chemically induced cell therapies, has announced the successful completion of its Series B financing round, raising over RMB 100 million (USD 14.15 million). The financing was co-led by Orinno Capital, with additional investments from Optics Valley Industrial Investment and other participants. The funds raised will be directed towards the advancement of iRegene’s Parkinson’s disease treatment products, NouvNeu001/NouvNeu003a, and its ophthalmic therapy, NouvSight001, in both the United States and China, as well as the company’s industrialization efforts.
Established in 2017, iRegene Therapeutics operates at the forefront of regenerative medicine, focusing on the use of small molecule chemical transcriptional regulation to induce pluripotent stem cells (iPSCs). The company’s flagship product in its pipeline, NouvNeu001, is the world’s first chemical induction-based universal cell therapy to enter clinical trials. It received approval for a Phase I/II study in China in August 2023, with initial results indicating good safety and significant improvements in motor function and quality of life for the subjects involved. Furthermore, NouvSight001 received orphan drug designation (ODD) in the US in March of this year for the treatment of retinitis pigmentosa, highlighting the potential impact of iRegene’s therapies on patients with rare diseases.- Flcube.com
